NURS 5334 ADVANCED PHARMACOLOGY
ENDOCRINE & DIABETES MEDICATION
STUDY GUIDE LATEST UPDATE 2026-2027
48 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze the pharmacodynamic and pharmacokinetic distinctions among endocrine and antidiabetic drug
classes to select optimal therapy in complex, comorbid presentations
2 Synthesize current ADA/EASD, ATA, and Endocrine Society recommendations with patient-specific
variables to justify or reject therapeutic regimens
3 Evaluate drug-induced endocrine dysfunction, monitoring parameters, and adverse-effect profiles to
ensure safe prescribing and follow-up
4 NURS 5334 Advanced Pharmacology Endocrine & Diabetes Medication Study Guide Latest Update 2026
5 2027
6 Foundations of Advanced Pharmacology - Endocrine & Diabetes Medications
7 Applied Advanced Pharmacology - Endocrine & Diabetes Medications
8 Advanced Advanced Pharmacology - Endocrine & Diabetes Medications
9 Advanced Pharmacology - Endocrine & Diabetes Medications Review
ABSTRACT
This study document brings together 48 carefully worded exam questions drawn from NURS 5334
Advanced Pharmacology Endocrine & Diabetes Medication Study Guide Latest Update 2026-2027,
with the strongest emphasis placed on Analyze the pharmacodynamic and pharmacokinetic
distinctions among endocrine and antidiabetic drug classes to select optimal therapy in complex,
comorbid presentations, Synthesize current ADA/EASD, ATA, and Endocrine Society
recommendations with patient-specific variables to justify or reject therapeutic regimens, Evaluate
drug-induced endocrine dysfunction, monitoring parameters and and adverse-effect profiles to
ensure safe prescribing and follow-up. Every item follows the wording style and level of reasoning
you meet in the real paper, and each one is paired with a clear rationale so the correct choice is
never a guess. Work through the set at your own pace, mark the questions that slow you down,
then come back to them until the reasoning feels automatic. Learners who revise this way walk into
the exam room recognising the pattern behind the questions instead of meeting them for the first
time. Keep going - steady, honest practice is what turns a difficult paper into a comfortable pass.
Page 1
,Q1 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
A patient with type 2 diabetes and a history of recurrent genital mycotic infections
is being considered for an SGLT2 inhibitor. Which mechanistic property best
explains this adverse effect and informs counseling?
A. Osmotic diuresis from glucosuria creates a glucose-rich urogenital environment that promotes
fungal colonization. CORRECT
B. Inhibition of renal sodium-glucose cotransport directly suppresses local immune defenses in
the genital tract.
C. Increased hepatic gluconeogenesis raises systemic glucose, indirectly seeding genital fungal
growth.
D. Reduced renal clearance of ketone bodies alkalinizes urine, favoring Candida overgrowth.
RATIONALE: SGLT2 inhibitors block proximal tubular glucose reabsorption, causing glucosuria
and an osmotically enriched, glucose-laden urogenital milieu that predisposes to mycotic
infections. The other options misattribute the mechanism to immune suppression, hepatic
glucose output, or urinary alkalinization, none of which are the primary driver.
Q2 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
Which statement most accurately reflects the cardiovascular and renal outcome
evidence for SGLT2 inhibitors in type 2 diabetes?
A. Benefit is limited to patients with baseline eGFR above 90 mL/min/1.73 m².
B. Reductions in heart failure hospitalization and CKD progression are seen across a broad
eGFR range, independent of glycemic control. CORRECT
C. Cardiovascular mortality reduction is attributable primarily to weight loss and improved
glycemic control.
D. Renal protection is mediated exclusively through blood pressure lowering.
RATIONALE: Landmark trials (EMPA-REG, DAPA-HF, CREDENCE, DAPA-CKD) demonstrate
cardiorenal benefits across a wide eGFR spectrum, largely independent of glucose lowering,
reflecting hemodynamic and metabolic mechanisms. The other options incorrectly restrict
eligibility, overstate glycemic/weight mediation, or reduce benefit to a single mechanism.
Page 2
, Q3 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
A patient using an insulin pump with rapid-acting analog experiences unexplained
postprandial hyperglycemia and occasional hypoglycemia at 3-4 hours. Which
pharmacokinetic property of the analog most likely contributes to this pattern?
A. Delayed onset with prolonged duration extending beyond the meal.
B. Rapid onset but a duration that can extend 3-5 hours, causing late postprandial hypoglycemia.
CORRECT
C. Absorption highly dependent on injection site blood flow, leading to erratic peaks.
D. Renal clearance that is saturable at therapeutic concentrations.
RATIONALE: Rapid-acting analogs (lispro, aspart, glulisine) have rapid onset but durations up to
3-5 hours, which can produce late postprandial hypoglycemia if dosing or timing is suboptimal.
Options A and C describe regular human insulin or site variability; D is not a recognized property
of these analogs.
Q4 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
Which pharmacodynamic feature distinguishes GLP-1 receptor agonists from
DPP-4 inhibitors in terms of incretin effect?
A. GLP-1 RAs raise endogenous GLP-1 levels, whereas DPP-4 inhibitors directly activate the
receptor.
B. GLP-1 RAs provide supraphysiologic receptor activation, while DPP-4 inhibitors only modestly
raise endogenous GLP-1. CORRECT
C. DPP-4 inhibitors produce greater weight loss than GLP-1 RAs.
D. Both classes equally reduce cardiovascular events in all patient populations.
RATIONALE: GLP-1 receptor agonists achieve pharmacologic, supraphysiologic receptor
stimulation, yielding robust A1C reduction and weight loss, whereas DPP-4 inhibitors merely
prevent incretin degradation, producing modest endogenous GLP-1 elevation. Options A and C
invert mechanisms/effects; D overstates DPP-4 inhibitor CV benefit.
Page 3
ENDOCRINE & DIABETES MEDICATION
STUDY GUIDE LATEST UPDATE 2026-2027
48 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze the pharmacodynamic and pharmacokinetic distinctions among endocrine and antidiabetic drug
classes to select optimal therapy in complex, comorbid presentations
2 Synthesize current ADA/EASD, ATA, and Endocrine Society recommendations with patient-specific
variables to justify or reject therapeutic regimens
3 Evaluate drug-induced endocrine dysfunction, monitoring parameters, and adverse-effect profiles to
ensure safe prescribing and follow-up
4 NURS 5334 Advanced Pharmacology Endocrine & Diabetes Medication Study Guide Latest Update 2026
5 2027
6 Foundations of Advanced Pharmacology - Endocrine & Diabetes Medications
7 Applied Advanced Pharmacology - Endocrine & Diabetes Medications
8 Advanced Advanced Pharmacology - Endocrine & Diabetes Medications
9 Advanced Pharmacology - Endocrine & Diabetes Medications Review
ABSTRACT
This study document brings together 48 carefully worded exam questions drawn from NURS 5334
Advanced Pharmacology Endocrine & Diabetes Medication Study Guide Latest Update 2026-2027,
with the strongest emphasis placed on Analyze the pharmacodynamic and pharmacokinetic
distinctions among endocrine and antidiabetic drug classes to select optimal therapy in complex,
comorbid presentations, Synthesize current ADA/EASD, ATA, and Endocrine Society
recommendations with patient-specific variables to justify or reject therapeutic regimens, Evaluate
drug-induced endocrine dysfunction, monitoring parameters and and adverse-effect profiles to
ensure safe prescribing and follow-up. Every item follows the wording style and level of reasoning
you meet in the real paper, and each one is paired with a clear rationale so the correct choice is
never a guess. Work through the set at your own pace, mark the questions that slow you down,
then come back to them until the reasoning feels automatic. Learners who revise this way walk into
the exam room recognising the pattern behind the questions instead of meeting them for the first
time. Keep going - steady, honest practice is what turns a difficult paper into a comfortable pass.
Page 1
,Q1 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
A patient with type 2 diabetes and a history of recurrent genital mycotic infections
is being considered for an SGLT2 inhibitor. Which mechanistic property best
explains this adverse effect and informs counseling?
A. Osmotic diuresis from glucosuria creates a glucose-rich urogenital environment that promotes
fungal colonization. CORRECT
B. Inhibition of renal sodium-glucose cotransport directly suppresses local immune defenses in
the genital tract.
C. Increased hepatic gluconeogenesis raises systemic glucose, indirectly seeding genital fungal
growth.
D. Reduced renal clearance of ketone bodies alkalinizes urine, favoring Candida overgrowth.
RATIONALE: SGLT2 inhibitors block proximal tubular glucose reabsorption, causing glucosuria
and an osmotically enriched, glucose-laden urogenital milieu that predisposes to mycotic
infections. The other options misattribute the mechanism to immune suppression, hepatic
glucose output, or urinary alkalinization, none of which are the primary driver.
Q2 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
Which statement most accurately reflects the cardiovascular and renal outcome
evidence for SGLT2 inhibitors in type 2 diabetes?
A. Benefit is limited to patients with baseline eGFR above 90 mL/min/1.73 m².
B. Reductions in heart failure hospitalization and CKD progression are seen across a broad
eGFR range, independent of glycemic control. CORRECT
C. Cardiovascular mortality reduction is attributable primarily to weight loss and improved
glycemic control.
D. Renal protection is mediated exclusively through blood pressure lowering.
RATIONALE: Landmark trials (EMPA-REG, DAPA-HF, CREDENCE, DAPA-CKD) demonstrate
cardiorenal benefits across a wide eGFR spectrum, largely independent of glucose lowering,
reflecting hemodynamic and metabolic mechanisms. The other options incorrectly restrict
eligibility, overstate glycemic/weight mediation, or reduce benefit to a single mechanism.
Page 2
, Q3 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
A patient using an insulin pump with rapid-acting analog experiences unexplained
postprandial hyperglycemia and occasional hypoglycemia at 3-4 hours. Which
pharmacokinetic property of the analog most likely contributes to this pattern?
A. Delayed onset with prolonged duration extending beyond the meal.
B. Rapid onset but a duration that can extend 3-5 hours, causing late postprandial hypoglycemia.
CORRECT
C. Absorption highly dependent on injection site blood flow, leading to erratic peaks.
D. Renal clearance that is saturable at therapeutic concentrations.
RATIONALE: Rapid-acting analogs (lispro, aspart, glulisine) have rapid onset but durations up to
3-5 hours, which can produce late postprandial hypoglycemia if dosing or timing is suboptimal.
Options A and C describe regular human insulin or site variability; D is not a recognized property
of these analogs.
Q4 ANALYZE THE PHARMACODYNAMIC AND PHARMACOKINETIC DISTINCTIONS AMONG
ENDOCRINE AND ANTIDIABETIC DRUG CLASSES TO SELECT OPTIMAL THERAPY IN
COMPLEX, COMORBID PRESENTATIONS
Which pharmacodynamic feature distinguishes GLP-1 receptor agonists from
DPP-4 inhibitors in terms of incretin effect?
A. GLP-1 RAs raise endogenous GLP-1 levels, whereas DPP-4 inhibitors directly activate the
receptor.
B. GLP-1 RAs provide supraphysiologic receptor activation, while DPP-4 inhibitors only modestly
raise endogenous GLP-1. CORRECT
C. DPP-4 inhibitors produce greater weight loss than GLP-1 RAs.
D. Both classes equally reduce cardiovascular events in all patient populations.
RATIONALE: GLP-1 receptor agonists achieve pharmacologic, supraphysiologic receptor
stimulation, yielding robust A1C reduction and weight loss, whereas DPP-4 inhibitors merely
prevent incretin degradation, producing modest endogenous GLP-1 elevation. Options A and C
invert mechanisms/effects; D overstates DPP-4 inhibitor CV benefit.
Page 3
